BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26518164)

  • 1. Interferon-α2b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels.
    Su Y; Cheng R; Zhang J; Qian J; Diao C; Ran J; Zhang H; Li L
    Life Sci; 2015 Dec; 143():18-26. PubMed ID: 26518164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway.
    Xie C; Xie DY; Lin BL; Zhang GL; Wang PP; Peng L; Gao ZL
    Br J Cancer; 2013 Sep; 109(5):1198-205. PubMed ID: 23887606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered bone marrow-derived mesenchymal stem cells co-expressing IFN-γ and IL-10 inhibit hepatocellular carcinoma by modulating MAPK pathway.
    Wang H; Wang J; Shi X; Ding Y
    J BUON; 2017; 22(6):1517-1524. PubMed ID: 29332347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Lefty in the anti tumor activity of human adult liver stem cells.
    Cavallari C; Fonsato V; Herrera MB; Bruno S; Tetta C; Camussi G
    Oncogene; 2013 Feb; 32(7):819-26. PubMed ID: 22469982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
    Jiang W; Zhang C; Tian Z; Zhang J
    Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
    Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
    Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
    J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine CCL15 Mediates Migration of Human Bone Marrow-Derived Mesenchymal Stem Cells Toward Hepatocellular Carcinoma.
    Gao Y; Zhou Z; Lu S; Huang X; Zhang C; Jiang R; Yao A; Sun B; Wang X
    Stem Cells; 2016 Apr; 34(4):1112-22. PubMed ID: 26763650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo.
    Yano H; Ogasawara S; Momosaki S; Akiba J; Kojiro S; Fukahori S; Ishizaki H; Kuratomi K; Basaki Y; Oie S; Kuwano M; Kojiro M
    Liver Int; 2006 Oct; 26(8):964-75. PubMed ID: 16953837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
    Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
    Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma.
    Mi F; Gong L
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28659496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic Resonance Gd-RGD Imaging Study of Hepatocellular Carcinoma with High and Low Metastatic Potential before and after Human Bone Marrow-derived Mesenchymal Stem Cell Intervention.
    Li TR; Yu MH; Huang XB; Yang ZJ; Lu GM; Li YJ
    Chin Med J (Engl); 2017 Nov; 130(21):2591-2600. PubMed ID: 29067958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.
    Dai M; Liu J; Chen DE; Rao Y; Tang ZJ; Ho WZ; Dong CY
    Cancer Gene Ther; 2012 Feb; 19(2):77-83. PubMed ID: 21959967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch1 activation contributes to tumor cell growth and proliferation in human hepatocellular carcinoma HepG2 and SMMC7721 cells.
    Gao J; Dong Y; Zhang B; Xiong Y; Xu W; Cheng Y; Dai M; Yu Z; Xu H; Zheng G
    Int J Oncol; 2012 Nov; 41(5):1773-81. PubMed ID: 22922832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma.
    Sun Q; Wang R; Wang Y; Luo J; Wang P; Cheng B
    Oncol Rep; 2014 Feb; 31(2):933-9. PubMed ID: 24336972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour-bearing mice.
    Liu QW; Li JY; Zhang XC; Liu Y; Liu QY; Xiao L; Zhang WJ; Wu HY; Deng KY; Xin HB
    J Cell Mol Med; 2020 Sep; 24(18):10525-10541. PubMed ID: 32798252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma.
    Roh V; Laemmle A; Von Holzen U; Stroka D; Dufour JF; Hunt KK; Candinas D; Vorburger SA
    Cancer Gene Ther; 2008 Oct; 15(10):636-44. PubMed ID: 18535617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2.
    Zhu B; Sun L; Luo W; Li M; Coy DH; Yu L; Yu W
    Oncotarget; 2017 Apr; 8(14):23289-23302. PubMed ID: 28423575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.